Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.41 |
| ▸ | RAF1 | P04049 | 1/20 | 0.40 |
| ▸ | PNLIP | P16233 | 1/20 | 0.40 |
| ▸ | HPGDS | O60760 | 1/20 | 0.39 |
| ▸ | PTGDR | Q13258 | 2/20 | 0.39 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.39 |
| ▸ | PPARG | P37231 | 3/20 | 0.38 |
| ▸ | SIRT2 | Q8IXJ6 | 4/20 | 0.37 |
| ▸ | SIRT1 | Q96EB6 | 4/20 | 0.37 |
| ▸ | SIRT3 | Q9NTG7 | 3/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.37 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.37 |
| ▸ | GRM5 | P41594 | 1/20 | 0.36 |
| ▸ | ESRRA | P11474 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3505758 | 0.84 | EGFR (0.52) | EGFRERBB2PTGDRPTGDR2 | |
| SCHEMBL3484636 | 0.83 | MEN1 (0.52) | SIRT2SIRT1SIRT3 | |
| SCHEMBL3485177 | 0.81 | ACACB (0.43) | EGFRERBB2PNLIPHPGDSGRM4 | |
| SCHEMBL3484639 | 0.80 | GRM4 (0.42) | EGFRERBB2PNLIPGRM4NR1H4 | |
| SCHEMBL3484557 | 0.77 | ANO1 (0.45) | EGFRERBB2RAF1EPHX2 | |
| SCHEMBL3483771 | 0.77 | EGFR (0.39) | EGFRERBB2PNLIPPTGDRPTGDR2 | |
| SCHEMBL3506314 | 0.76 | POLB (0.48) | PNLIP | |
| SCHEMBL28880745 | 0.75 | PNLIP (0.46) | PNLIPNR1H4ESRRA | |
| SCHEMBL3506152 | 0.73 | MRGPRX4 (0.46) | EGFRERBB2PNLIP | |
| SCHEMBL2034696 | 0.73 | PPARG (0.50) | PPARGCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100004238-A1 | FUSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-01-07 | — | — | US | disclosed |
| EP-2103620-A1 | FUSED HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2009-09-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004238-A1 | FUSED HETEROCYCLIC COMPOUND | ERBB2, ROS1, FLT3 | EGFR 13/4885ERBB2 1/4885RAF1 129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.